Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

Clinical Transplantation

Volumn 15, Issue 2, 2001, Pages 123-130

  Kovarik, John M ^a   Pescovitz, Mark D ^b   Sollinger, Hans W ^c   Kaplan, Bruce ^d   Legendre, Christophe ^e   Salmela, Kaija ^f   Book, Benita K ^b   Gerbeau, Christophe ^g   Girault, Daniele ^a   Somberg, Kenneth ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Medical Center ^*

^c INDIANA UNIVERSITY   (United States)

^d University of Wisconsin Health   (United States)

^e Saint Barnabas Health Care System   (United States)

^f SAINT LOUIS HOSPITAL   (France)

^g University of Helsinki HIP   (Switzerland)

Author keywords

Antibodies; Azathioprine; Basiliximab; Immune response; Mycophenolate mofetil

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; THYMOCYTE ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PARAMETER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; TIME;

EID: 0035098094     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2001.150208.x     Document Type: Article

References (14)

1. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
2. Reduction in the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody
3. A multicenter, double-blind, placebo-controlled study of basiliximab in combination with triple therapy including azathioprine for the prevention of acute rejection episodes in renal allograft patients
4. A multi-center, randomized trial of Simulect with early Neoral vs Atgam with delayed Neoral in renal transplantation: A 6-month analysis
5. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation
6. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
7. Reduced human IgG anti-Atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil
8. Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: An application to basiliximab in renal transplantation
9. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
10. Immunomodulators in the treatment of selected autoimmune diseases
11. Suppression of the humoral immune response by mycophenolate mofetil
12. The effect of azathioprine on gammaglobulin synthesis in man
13. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients